SynthesisNPJ primary care respiratory medicine2026
Economic evaluations of screening and case-finding for Chronic Obstructive Pulmonary Disease (COPD): a systematic review.
Synthesis in NPJ primary care respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Pilot Feasibility Study of a Metronome-Cued mHealth System to Promote Walking Exercise in COPD.Healthcare (Basel, Switzerland) · 2026Article
- Explainable Machine Learning Model Based on Routine Admission Laboratory Tests for Predicting New-Onset Hypoalbuminemia in Hospitalized Older Patients with Acute Exacerbation of COPD.Clinical interventions in aging · 2026Article
- Integrating Machine Learning for Early COPD Prediction in Lung Cancer Patients: A Focus on Systemic Coagulation-Inflammation Index.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) imposes significant health and economic burdens globally. Screening and case-finding strategies are increasingly recognized as critical methods to enhance early diagnosis and management of COPD. It is important to understand the economic impact and cost-effectiveness of these strategies to inform the population health policies and real-world practice. In this study, we aim to summarize and compare the economic evaluations of COPD screening and case-finding strategies. We searched PubMed, EMBASE, Cochrane Library, and NHS economic databases for all published studies up to April 2025 that reported economic outcomes, including cost-effectiveness, budget impact, or cost analysis, related to screening and case-finding of COPD. Data extraction included study type, target population, methods, cost perspectives, and outcome measures. Findings were synthesized narratively. This systematic review was registered in PROSPERO (CRD42024516534). We identified 18 eligible studies that met the inclusion criteria, including 11 empirical and 7 modeling studies. A range of screening and case-finding approaches were evaluated, with most studies (n = 16) employing questionnaires either as standalone tools (n = 14) or for pre-screening purposes before the portable spirometer test (n = 8). Portable spirometers were also commonly used (n = 10). The economic outcome measures varied across studies, including cost per additional case detected, cost per quality-adjusted-life-year (QALY) gained, and program-level budget impact. Healthcare sector and payer's perspectives were the most commonly adopted. While studies consistently suggested that targeted screening strategies were likely to be cost-effective, considerable heterogeneity in study designs, target populations, and economic measures limited direct comparisons between the strategies. COPD screening and case-finding showed potential of being cost-effective preventive strategies, particularly for high-risk groups. However, the lack of standardized descriptions for the details of the implemented strategies and the diverse outcome measures reported across existing studies limits the comparability between these strategies. Future research is needed to assess the long-term economic impact on healthcare systems and to explore personalized compared with one-size-fits-all screening strategies for COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.